Thackray Helen M.'s Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Apr 5, 2023
- Accession no.
- 0001127602-23-012587
- Filed
- Apr 5, 2023
- Trade date
- Apr 3, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $58.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thackray Helen M.CIK 0001589725 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2023 | Common Stock | SSaleDisposed | −7,000 | $8.29 | −$58,030 | 207,275 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.